Thursday, October 22, 2026

Active Fund Managers Cite AI as Alpha Killer as Passive Strategies Gain Ground

Prominent value investor Guy Spier declares traditional stock-picking "doesn't work any more" as AI tools erode active managers' research edge. Spier warns his probability of outperformance has declined further as automation makes overlooked market opportunities scarce. Passive vehicles now command higher analyst ratings, with Vanguard's S&P 500 Growth ETF carrying 40%+ upside targets.

LM Salvado
LM Salvado

March 30, 2026

Active Fund Managers Cite AI as Alpha Killer as Passive Strategies Gain Ground
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Guy Spier, founder of Aquamarine Fund, says "Buffett-and-Munger-style stockpicking doesn't work any more" as artificial intelligence reshapes competitive dynamics in asset management.1

Spier attributes the shift to AI streamlining research processes that once gave active managers an edge. "The probability that I'll outperform has reduced even more," he states, adding that "it's grown increasingly difficult to identify overlooked corners of the market."1

The comments highlight structural pressure on active strategies as machine learning tools democratize access to data analysis and pattern recognition. AI-driven screening now replicates months of fundamental research in hours, compressing the time advantage skilled analysts historically enjoyed.

Passive vehicles are capturing the benefits. Vanguard S&P 500 ETF carries a Moderate Buy rating with 31% upside, while Vanguard S&P 500 Growth ETF holds a Strong Buy rating with over 40% upside potential.1 The ratings gap suggests analysts expect passive indexing to deliver superior risk-adjusted returns as active alpha deteriorates.

The shift creates asymmetric risks for active managers. Funds charging 1-2% management fees must now beat benchmarks despite AI reducing information advantages. As natural language processing tools parse earnings calls and alternative data sets become commoditized, the pool of undervalued securities shrinks.

For traders, this implies tightening dispersions in stock returns as AI narrows valuation gaps faster than human analysts can exploit them. High-frequency algorithms and quantitative funds deploying machine learning already dominate short-term mispricings, leaving traditional stock-pickers competing for diminishing opportunities in longer time horizons.

The competitive erosion may accelerate capital rotation from active to passive allocations. Institutional investors face mounting pressure to justify active fees when index-tracking strategies deliver comparable or superior outcomes at fraction of the cost.

Spier's acknowledgment that AI has "streamlined the painstaking research once viewed as a key advantage for active managers" signals a potential inflection point.1 If veteran value investors concede structural disadvantage, the multi-decade shift toward passive indexing could intensify.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com